TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer

Although TP53 mutations have been widely studied in lung cancer, the majority of studies have focused on exons 5-8 of the gene. In addition, TP53 mutations in Korean patients with lung cancers have not been investigated. We searched for mutations in the entire coding exons, including splice sites of the gene, in Korean patients with non-small cell lung cancer (NSCLC). Mutations of the gene were determined by direct sequencing in 176 NSCLCs. Sixty-nine mutations (62 different mutations) were identified in 65 tumors. Of the 62 mutations, 12 were novel mutations. TP53 mutations were more frequent in males, ever-smokers and squamous cell carcinomas than in females, never-smokers and adenocarcinomas, respectively (all comparisons, P<0.001). Missense mutations were most common (52.2%), but frameshift, nonsense, and splice-site mutations were frequently observed at frequencies of 18.8%, 15.9% and 10.1%, respectively. Of the 69 mutations, 9 (13.0%) were found in the oligomerization domain. In addition, the proportion of mutations in the oligomerization domain was significantly higher in adenocarcinomas than in squamous cell carcinomas (23.5% vs. 2.9%, P=0.01). Our study provides clinical and molecular characteristics of TP53 mutations in Korean patients with NSCLCs.

[1]  M. Meyerson,et al.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.

[2]  D. Ryberg,et al.  p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. , 1994, Cancer Research.

[3]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[4]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[5]  W. Travis,et al.  The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.

[6]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[7]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[8]  W P Bennett,et al.  Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer , 1999, The Journal of pathology.

[9]  J. Varley,et al.  Characterization of germline TP53 splicing mutations and their genetic and functional analysis , 2001, Oncogene.

[10]  R. Ueda,et al.  Distinct mutational spectrum of the p53 gene in lung cancers from Chinese women in Hong Kong. , 1995, Cancer research.

[11]  T. Sekiya,et al.  Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. , 1992, Cancer research.

[12]  C. Harris,et al.  p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. , 1999, Mutation research.

[13]  J. Jassem,et al.  TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis , 1997, Oncogene.

[14]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[15]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[16]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[17]  Hojoong Kim,et al.  Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study. , 2009, Lung cancer.

[18]  高木幸浩.  Distinct mutational spectrum of the p53 gene in lung cancers from Chinese women in Hong Kong , 1996 .

[19]  T. Soussi,et al.  p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.

[20]  C Béroud,et al.  p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis , 2000, Human mutation.

[21]  P. Chène,et al.  The role of tetramerization in p53 function , 2001, Oncogene.

[22]  Toshihide Tsuda,et al.  The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.

[23]  C. Harris,et al.  Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. , 1996, Cancer research.

[24]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[25]  J. Park,et al.  EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. , 2007, Cancer genetics and cytogenetics.

[26]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[27]  A. Levine,et al.  The Spectrum of Mutations at the p53 Locus , 1995, Annals of the New York Academy of Sciences.